Maternal care for anti-D [Rh] antibodies, second trimester (other fetus)
ICD-10 O36.0129 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, second trimester (other fetus).
Maternal care for anti-D [Rh] antibodies during the second trimester is critical for managing potential fetal complications arising from Rh incompatibility. This condition occurs when an Rh-negative mother carries an Rh-positive fetus, leading to the production of anti-D antibodies that can cross the placenta and affect the fetus. The presence of these antibodies can lead to hemolytic disease of the newborn (HDN), characterized by fetal anemia, jaundice, and potential growth restriction. Monitoring during this period is essential to assess fetal well-being, including growth parameters and signs of distress. Regular ultrasounds and Doppler studies may be employed to evaluate fetal blood flow and overall health. The management plan may involve administering Rh immunoglobulin (RhoGAM) to prevent antibody formation in future pregnancies, and close monitoring of fetal development is crucial to mitigate risks associated with fetal distress and growth restriction.
Detailed records of maternal blood type, antibody screening results, and fetal monitoring.
Management of Rh incompatibility in a pregnant patient with a history of anti-D antibodies.
Ensure accurate coding of maternal and fetal conditions, and document any interventions or treatments provided.
Comprehensive assessments of fetal growth, well-being, and any interventions required.
Monitoring a fetus with suspected hemolytic disease due to maternal anti-D antibodies.
Focus on high-risk factors and ensure all relevant diagnostic tests are documented.
Used to monitor fetal growth and well-being in patients with anti-D antibodies.
Document indications for ultrasound and findings related to fetal health.
Ensure that the ultrasound report includes details relevant to Rh incompatibility.
Accurate coding of O36.0129 is crucial for ensuring appropriate management of pregnancies complicated by anti-D antibodies. It helps in tracking maternal and fetal health, guiding treatment decisions, and ensuring proper reimbursement for the care provided.
